Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Less invasive ablation treatment in patients with small renal tumors has a comparable risk for tumor progression to surgical resection, with fewer complications and shorter hospital stays.
Sara Coca Membribes: KIM1 in Advanced RCC Published in European Urology / Begoña P Valderrama, cancer, Charles Mein, Charlotte Ackermann, Cristina Suárez,
Experts discussed the clinical implications of the LITESPARK-011 trial of belzutifan plus lenvatinib following a presentation of efficacy findings at ASCO GU.
Tyrosine kinase inhibitors (TKIs) combined with immunotherapy have improved outcomes in advanced renal cell carcinoma (aRCC), yet resistance persists. This group presents single-cell transcriptomic profiling of aRCC patients treated with TKIs and immune checkpoint inhibitors, uncovering an ...
Although the use of tyrosine kinase inhibitors (TKIs), such as sunitinib, has led to impressive advancements in the treatment of clear cell renal cell carcinoma (ccRCC), primary or acquired resistance to sunitinib remains elusive. Here, we report that death receptor 5 (DR5) is upregulated in ...
A revolutionary non-surgical treatment developed at University Hospital Southampton is helping to transform care for kidney cancer.
Investigators sought to determine the effect of diabetes and metformin on renal cell carcinoma (RCC) outcomes.
Explore 10 ongoing clinical trials investigating immunotherapy strategies in renal cancer, including checkpoint inhibitors, HIF-2α inhibitors, microbiome-based therapies, and surgery-integrated approaches reshaping kidney cancer treatment.
PD-L1 May Predict Response to TKIs, VEGFs in Metastatic Clear Cell Renal Cell Carcinoma · Axitinib Shows Activity in Metastatic Renal Cell Carcinoma.
Brain metastases (BrM) in metastatic clear-cell renal cell carcinoma (m-ccRCC) are resistant to most systemic therapies, but respond better to cabozantinib. We documented intracranial response on common systemic therapies for m-ccRCC, described molecular mechanisms underlying efficacy or ...
No results found.
Articles from Kidney Cancer UK
Kidney Cancer UK Paper Published in BJU International
A decade-long insight into patient views on kidney cancer care delivery
A paper on our Kidney Cancer UK 10-Year ...
First NKCA annual report recommends reduction in unwarranted variation
The first annual State of the Nation Report from the National Kidney Cancer Audit (NKCA) highlights unwarranted ...
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
"Patients with advanced renal cancer often have a long and difficult ... kidney cancer," added Darren R. Feldman, MD, Medical Oncologist ...
Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC
Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.
Belzutifan Improves PFS in ccRCC Subgroups
Findings from a subgroup analysis of the phase 3 LITESPARK-005 trial showed that belzutifan demonstrated superior efficacy and safety outcomes vs everolimus across prespecified subgroups.
No results found.